Pelitinib (Fig. 1A) as an EGFR-TK inhibitor has been evaluated in phase 2 clinical trials for colorectal cancer and NSCLC [35, 40], but the molecular mechanisms of its anti-cancer effects from the perspective of EMT on HCC cell lines have not been studied to date. Here, EGFR is linked to colorectal cancer.